MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/03/6401-113-122$20.00
Mol Pharmacol 64:113-122, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ripp, S. L.
Right arrow Articles by Prough, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ripp, S. L.
Right arrow Articles by Prough, R. A.

Regulation of CYP2C11 by Dehydroepiandrosterone and Peroxisome Proliferators: Identification of the Negative Regulatory Region of the Gene

Sharon L. Ripp1, K. Cameron Falkner, Mary L. Pendleton, Viola Tamasi, and Russell A. Prough

Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, Kentucky

Treatment of rats with peroxisome proliferators is known to affect gene expression, including suppression of CYP2C11. The current study examined the mechanism of negative regulation of CYP2C11, comparing the effects of a classic peroxisome proliferator, nafenopin, with those of the steroid dehydroepiandrosterone (DHEA). In vivo dose-response experiments for DHEA were carried out with rats. Only the highest dose of DHEA in the diet (0.45%), a dose previously shown to produce peroxisome proliferation, caused suppression of CYP2C11 expression. Lower doses of DHEA (0.012 to 0.20% in diet) had little effect on CYP2C11 expression. In HepG2 cells, negative regulation of a CYP2C11 reporter gene by nafenopin required coexpression of PPAR{alpha}, whereas negative regulation by DHEA did not. Deletion analysis revealed that the responsive region for both DHEA and nafenopin was between -108 and -60 relative to the transcription start site. Mutations in several putative transcription factor binding sites in the 5'-flanking region of CYP2C11 were produced. A mutation at -121 bp significantly diminished basal expression of CYP2C11 but did not affect negative regulation by DHEA or nafenopin. A mutation at -75 bp had only a small effect on basal expression but completely abolished negative regulation by DHEA and nafenopin. Gel shift experiments indicated that PPAR{alpha}/RXR{alpha} heterodimers do not bind DNA in this region. Therefore, the sequence at -75 bp of CYP2C11 is necessary for negative regulation by both DHEA and nafenopin. However, the upstream events leading to suppression at this site must differ for DHEA and nafenopin.


Received September 9, 2002; accepted April 2, 2003

Address correspondence to: Dr. Russell A. Prough, Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, KY 40292. E-mail: russ.prough{at}louisville.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
V. Tamasi, K. K. M. Miller, S. L. Ripp, E. Vila, T. E. Geoghagen, and R. A. Prough
Modulation of Receptor Phosphorylation Contributes to Activation of Peroxisome Proliferator Activated Receptor {alpha} by Dehydroepiandrosterone and Other Peroxisome Proliferators
Mol. Pharmacol., March 1, 2008; 73(3): 968 - 976.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. C. Falkner, J. K. Ritter, and R. A. Prough
Regulation of the Rat UGT1A6 by Glucocorticoids Involves a Cryptic Glucocorticoid Response Element
Drug Metab. Dispos., February 1, 2008; 36(2): 409 - 417.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Kohalmy, V. Tamasi, L. Kobori, E. Sarvary, J.-M. Pascussi, P. Porrogi, D. Rozman, R. A. Prough, U. A. Meyer, and K. Monostory
Dehydroepiandrosterone Induces Human CYP2B6 through the Constitutive Androstane Receptor
Drug Metab. Dispos., September 1, 2007; 35(9): 1495 - 1501.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
V. Y. Ng, Y. Huang, L. M. Reddy, J. R. Falck, E. T. Lin, and D. L. Kroetz
Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor {alpha}
Drug Metab. Dispos., July 1, 2007; 35(7): 1126 - 1134.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. A. Spector and A. W. Norris
Action of epoxyeicosatrienoic acids on cellular function
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. C. Corton and P. J. Lapinskas
Peroxisome Proliferator-Activated Receptors: Mediators of Phthalate Ester-Induced Effects in the Male Reproductive Tract?
Toxicol. Sci., January 1, 2005; 83(1): 4 - 17.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. S. Riddick, C. Lee, A. Bhathena, Y. E. Timsit, P.-Y. Cheng, E. T. Morgan, R. A. Prough, S. L. Ripp, K. K. M. Miller, A. Jahan, et al.
TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS
Drug Metab. Dispos., April 1, 2004; 32(4): 367 - 375.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. K. M. Miller, J. Cai, S. L. Ripp, W. M. Pierce Jr., T. H. Rushmore, and R. A. Prough
STEREO- AND REGIOSELECTIVITY ACCOUNT FOR THE DIVERSITY OF DEHYDROEPIANDROSTERONE (DHEA) METABOLITES PRODUCED BY LIVER MICROSOMAL CYTOCHROMES P450
Drug Metab. Dispos., March 1, 2004; 32(3): 305 - 313.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics